AU2018312441B2 - Antibody binding active alpha-synuclein - Google Patents
Antibody binding active alpha-synuclein Download PDFInfo
- Publication number
- AU2018312441B2 AU2018312441B2 AU2018312441A AU2018312441A AU2018312441B2 AU 2018312441 B2 AU2018312441 B2 AU 2018312441B2 AU 2018312441 A AU2018312441 A AU 2018312441A AU 2018312441 A AU2018312441 A AU 2018312441A AU 2018312441 B2 AU2018312441 B2 AU 2018312441B2
- Authority
- AU
- Australia
- Prior art keywords
- synuclein
- active
- antibody
- sample
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540435P | 2017-08-02 | 2017-08-02 | |
| US62/540,435 | 2017-08-02 | ||
| PCT/CA2018/050952 WO2019023809A1 (en) | 2017-08-02 | 2018-08-02 | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEINE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018312441A1 AU2018312441A1 (en) | 2020-02-06 |
| AU2018312441B2 true AU2018312441B2 (en) | 2024-10-17 |
Family
ID=65232133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018312441A Active AU2018312441B2 (en) | 2017-08-02 | 2018-08-02 | Antibody binding active alpha-synuclein |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11098108B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3661961A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7204235B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102826089B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111225923B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018312441B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020001970A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272361B2 (cg-RX-API-DMAC7.html) |
| SA (1) | SA520411188B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019023809A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
| IL270361B2 (en) | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| EP3985022A4 (en) * | 2019-06-14 | 2023-08-02 | ABL Bio, Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE |
| IL293108A (en) * | 2019-11-19 | 2022-07-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein, and methods of using them |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| KR102505164B1 (ko) * | 2020-09-29 | 2023-02-28 | 서울대학교산학협력단 | 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물 |
| CN113912713B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 一种抗α-突触核蛋白的单克隆抗体及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3823313A1 (de) | 1988-07-09 | 1990-01-11 | Henkel Kgaa | Fussbodenreinigungsgeraet |
| US20040143093A1 (en) | 2002-07-11 | 2004-07-22 | Ralph Zahn | Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| WO2009152607A1 (en) * | 2008-06-16 | 2009-12-23 | Ottawa Hospital Research Institute | Methods and kits for diagnosing neurodegenerative disease |
| HRP20150831T1 (hr) | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| CN110655573B (zh) * | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| EP2807188B1 (en) * | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| EA035517B1 (ru) | 2014-03-06 | 2020-06-29 | Нэшнл Рисеч Каунсил Оф Канада | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения |
| EP3114142B1 (en) | 2014-03-06 | 2019-06-05 | National Research Council of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| JP6541237B2 (ja) | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子1受容体特異的抗体及びそれらの使用 |
| CN103983778B (zh) * | 2014-05-08 | 2016-04-13 | 首都医科大学宣武医院 | 一种检测受实验者体液体外促进疾病相关蛋白聚合能力的方法 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
-
2018
- 2018-08-02 EP EP18840781.1A patent/EP3661961A4/en active Pending
- 2018-08-02 JP JP2020528498A patent/JP7204235B2/ja active Active
- 2018-08-02 BR BR112020001970-4A patent/BR112020001970A2/pt active Search and Examination
- 2018-08-02 KR KR1020207003980A patent/KR102826089B1/ko active Active
- 2018-08-02 AU AU2018312441A patent/AU2018312441B2/en active Active
- 2018-08-02 IL IL272361A patent/IL272361B2/en unknown
- 2018-08-02 CN CN201880051765.4A patent/CN111225923B/zh active Active
- 2018-08-02 WO PCT/CA2018/050952 patent/WO2019023809A1/en not_active Ceased
- 2018-08-02 US US16/635,943 patent/US11098108B2/en active Active
-
2020
- 2020-01-29 SA SA520411188A patent/SA520411188B1/ar unknown
-
2021
- 2021-07-21 US US17/381,661 patent/US11919947B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019023809A1 (en) | 2019-02-07 |
| US11098108B2 (en) | 2021-08-24 |
| JP7204235B2 (ja) | 2023-01-16 |
| EP3661961A4 (en) | 2021-04-14 |
| CN111225923B (zh) | 2024-09-24 |
| CA3071634A1 (en) | 2019-02-07 |
| US20210139569A1 (en) | 2021-05-13 |
| BR112020001970A2 (pt) | 2020-08-04 |
| US11919947B2 (en) | 2024-03-05 |
| EP3661961A1 (en) | 2020-06-10 |
| KR102826089B1 (ko) | 2025-06-30 |
| IL272361B1 (en) | 2025-02-01 |
| IL272361A (en) | 2020-03-31 |
| US20210355202A1 (en) | 2021-11-18 |
| CN111225923A (zh) | 2020-06-02 |
| SA520411188B1 (ar) | 2023-01-08 |
| AU2018312441A1 (en) | 2020-02-06 |
| IL272361B2 (en) | 2025-06-01 |
| KR20200033880A (ko) | 2020-03-30 |
| JP2020529473A (ja) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11919947B2 (en) | Antibody binding active α-synuclein | |
| JP7227312B2 (ja) | 抗N3pGluアミロイドベータペプチド抗体およびその使用 | |
| CN109937210B (zh) | 用于治疗共核蛋白病的药剂、用途和方法 | |
| JP6290212B2 (ja) | タウオパチーの処置方法 | |
| CN111356701B (zh) | 抗α-突触核蛋白抗体及其用途 | |
| DK2282758T3 (en) | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS | |
| US9849165B2 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| JP6446443B2 (ja) | タウオパチーの処置方法 | |
| JP7449092B2 (ja) | 血液脳関門移動化合物及びその使用 | |
| JP2018139530A (ja) | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 | |
| KR20190133191A (ko) | 타우에 특이적으로 결합하는 결합 분자 | |
| JP7254931B2 (ja) | 抗アルファ-シヌクレイン抗体およびその使用 | |
| WO2025242094A1 (zh) | 靶向bdca2的抗体或其抗原结合片段及其应用 | |
| WO2023143425A1 (zh) | 改善认知障碍的方法 | |
| CA3071634C (en) | Antibody binding active alpha-synuclein | |
| HK40104165A (en) | Anti-tau antibodies and uses thereof | |
| HK40022840B (en) | ANTIBODIES TO α‐SYNUCLEIN AND USES THEREOF | |
| HK1231887A1 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| HK1185350B (en) | Oligomer-specific amyloid beta epitope and antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |